Jie Fan¹, Kaimin Zhang², Farooq Riaz², Yiping Hu^3,4, Jinjun Liu¹, Qinwen Wang^3,4 and Fan Pan²*

¹Department of Cardiology, Handan Central Hospital, China

*Corresponding Author: Fan Pan, Center for Cancer Research, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China.

Received: October 12, 2022; Published: October 19, 2022

Abstract

A classic autoimmune connective tissue disease, Systemic lupus erythematosus (SLE), causes injury to multiple organ systems. It has been demonstrated that tumor necrosis factor-induced protein 3 (TNFAIP3), typically represented as A20, is associated with the progression of SLE. However, it hasn’t been revealed how A20 is involved in modulating the role of A20 in SLE. In the current study, we determined that A20 was reduced in B cells collected from SLE patients, while the responsiveness of B cells was considerably elevated in SLE patients. Further investigation indicated overexpressing A20 in B cells restricted their proliferation and initiated their apoptosis. Moreover, trimethylation of histone H3 Lysine 4 (H3K4me3) was decreased in the A20 promoter of SLE B cells. Lysine demethylase 5A (Kdm5a) was significantly increased in B cells from SLE patients and negatively correlated with A20 expression. Further, Kdm5a knockdown increased the H3K4me3 level and A20 expression. More importantly, Kdm5a promoted the proliferation and inhibited the apoptosis of B cells in SLE via downregulation of A20. In general, Kdm5a promoted the proliferation and inhibited the apoptosis of B cells in SLE via downregulation of A20 by decreasing H3K4me3 enrichment level in the A20 promoter, suggesting a novel mechanism underlying SLE progression, and providing a promising therapeutic target for SLE.

Keywords: Systemic Lupus Erythematosus; Tumor Necrosis Factor-Induced Protein 3; B Cells; Lysine Demethylase 5A

References

1. Kiriakidou M and CL Ching. “Systemic Lupus Erythematosus”. Annals of Internal Medicine11 (2020): ITC81-ITC96.
2. Andrades C., et al. “Management of cardiovascular risk in systemic lupus erythematosus: a systematic review”. Lupus 13 (2017): 1407-1419.
3. Furie R and R Cervera. “Systemic lupus erythematosus”. Best Practice and Research: Clinical Rheumatology 3 (2017): 289-290.
4. Guery JC. “Why Is Systemic Lupus Erythematosus More Common in Women?” Joint Bone Spine3 (2019): 297-299.
5. Finzel S., et al. “[Pathogenesis of systemic lupus erythematosus]”. Z Rheumatology9 (2018): 789-798.
6. Fanouriakis A., et al. “Update omicronn the diagnosis and management of systemic lupus erythematosus”. Annals of the Rheumatic Diseases 1 (2021): 14-25.
7. Fillatreau S. “Regulatory functions of B cells and regulatory plasma cells”. Biomed Journal4 (2019): 233-242.
8. Feng Y., et al. “The pathological role of B cells in systemic lupus erythematosus: From basic research to clinical”. Autoimmunity2 (2020): 56-64.
9. Moulton VR., et al. “Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective”. Trends in Molecular Medicine 7 (2017): 615-635.
10. Wang T., et al. “Research Progress on Regulatory B Cells in Systemic Lupus Erythematosus”. BioMed Research International 2019 (2019): 7948687.
11. Morel L. “Immunometabolism in systemic lupus erythematosus”. Nature Reviews Rheumatology5 (2017): 280-290.
12. Ma K., et al. “Multiple Functions of B Cells in the Pathogenesis of Systemic Lupus Erythematosus”. International Journal of Molecular Sciences 23 (2019).
13. Zhang M., et al. “Roles of A20 in autoimmune diseases”. Immunology Research2 (2016): 337-344.
14. Mooney EC and SE Sahingur. “The Ubiquitin System and A20: Implications in Health and Disease”. Journal of Dental Research1 (2021): 10-20.
15. Li D., et al. “Down-regulation of A20 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus”. Journal of Clinical Immunology6 (2012): 1287-1291.
16. Ciccacci C., et al. “TNFAIP3 Gene Polymorphisms in Three Common Autoimmune Diseases: Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Primary Sjogren Syndrome-Association with Disease Susceptibility and Clinical Phenotypes in Italian Patients”. Journal of Immunology Research 2019 (2019): 6728694.
17. Yang GJ., et al. “The emerging role of KDM5A in human cancer”. Journal of Hematology and Oncology1 (2021): 30.
18. Kirtana R., et al. “Molecular mechanisms of KDM5A in cellular functions: Facets during development and disease”. Experimental Cell Research 2 (2020): 112314.
19. Petronikolou N., et al. “Extended Recognition of the Histone H3 Tail by Histone Demethylase KDM5A”. Biochemistry 5 (2020): 647-651.
20. Cho YW., et al. “Histone methylation regulator PTIP is required for PPARgamma and C/EBPalpha expression and adipogenesis”. Cell Metabolism1 (2009): 27-39.
21. Vereecke L., et al. “The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology”. Trends in Immunology8 (2009): 383-391.
22. Kim T., et al. “Synergistic activation of NF-kappaB by TNFAIP3 (A20) reduction and UBE2L3 (UBCH7) augment that synergistically elevate lupus risk”. Arthritis Research and Therapy1 (2020): 93.
23. Wang S., et al. “TALEN-mediated enhancer knockout influences TNFAIP3 gene expression and mimics a molecular phenotype associated with systemic lupus erythematosus”. Genes Immunity3 (2016): 165-170.
24. Shi X., et al. “Aberrant Low Expression of A20 in Tumor Necrosis Factor-alpha-stimulated SLE Monocytes Mediates Sustained NF-kappaB Inflammatory Response”. Immunology Investigation5 (2015): 497-508.
25. Tavares RM., et al. “The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity”. Immunity2 (2010): 181-191.
26. Chen Y., et al. “Epigenetic modification of nucleic acids: from basic studies to medical applications”. Chemical Society Reviews10 (2017): 2844-2872.
27. Zhao LY., et al. “Mapping the epigenetic modifications of DNA and RNA”. Protein Cell 11 (2020): 792-808.
28. Zhang Y., et al. “Overview of Histone Modification”. Advances in Experimental Medicine and Biology 1283 (2017): 1-16.
29. Zhang L., et al. “Epigenetics in Health and Disease”. Advances in Experimental Medicine and Biology 1253 (2020): 3-55.
30. Hyun K., et al. “Writing, erasing and reading histone lysine methylations”. Experimental and Molecular Medicine 4 (2017): e324.
31. Zhao H., et al. “TNFAIP3 downregulation mediated by histone modification contributes to T-cell dysfunction in systemic lupus erythematosus”. Rheumatology (Oxford) 5 (2017): 835-843.

Citation

Citation: Fan Pan., et al. “Histone Lysine Demethylase 5A Promotes the Proliferation and Inhibits the Apoptosis of B Cells in SLE". Acta Scientific Microbiology 5.11 (2022): 38-46.

Copyright

Copyright: © 2022 Fan Pan., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.